NCT02481414View on ClinicalTrials.gov

A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 14, 2022

Study Completion Date

September 14, 2022

Conditions
Cervical Intraepithelial Neoplasia
Interventions
BIOLOGICAL

PepCan

50 μg peptide + 0.3 mL Candin® per dose administered intradermally in the extremities

BIOLOGICAL

Candin®

0.3 mL Candin® per dose administered intradermally in the extremities

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER

NCT02481414 - A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions | Biotech Hunter | Biotech Hunter